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40-word-or-less summary: 
Analysis of COVID19 convalescents reveals that neutralizing antibody levels decline rapidly 
early after infection. Some clinical serological assay platforms give quantitative outputs that 
predict neutralizing antibody titer, but some have diagnostic sensitivity that deteriorates with 
time post infection.  
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Abstract 
 
Background – Understanding the longitudinal trajectory of SARS-CoV-2 antibodies is 
crucial for diagnosis of prior infection and predicting future immunity. 
 
Methods We conducted a longitudinal analysis of COVID19 convalescents, using 
neutralizing antibody assays and SARS-CoV-2 serologic assay platforms employing SARS-
CoV-2 spike (S) or nucleocapsid (N) antigens. 
 
Results Sensitivities of serologic assays to diagnose prior SARS-CoV-2 infection changed 
with time. One widely used commercial platform that had an initial sensitivity of >95% 
declined to 71% at 81-100 days post diagnosis. The trajectories of median binding antibody 
titers measured over ~3 to 4 months were not dependent on the use of SARS-CoV-2 N or S 
proteins as antigen. The median neutralization titer decreased by ~45% per month. Each 
serological assay gave quantitative antibody titers that correlated with SARS-CoV-2 
neutralization titers, but S-based serological assay measurements better predicted 
neutralization potency. Correlation between S-binding and neutralization titers deteriorated 
with time and decreases in neutralization titers were not predicted by changes in S-binding 
antibody titers. 
Conclusions – Different SARS-CoV-2 serologic assays are more or less well suited for 
surveillance versus prediction of serum neutralization potency. Extended follow up should 
facilitate the establishment of appropriate serologic correlates of protection against SARS-
CoV-2 reinfection. 
Key Words: SARS-CoV-2, COVID19, Serology, Neutralizing antibodies
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Introduction 
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
the causative agent of COVID-19, has resulted in a devastating global pandemic. Diagnosis 
of SARS-CoV-2 infection is principally dependent on RT-PCR using nasal and throat swabs, 
which is not ideally suited to mass population testing. RT-PCR-diagnosed case numbers 
have therefore underestimated the prevalence of SARS-CoV-2 infection, and serology 
assays must be deployed to determine the true number of infections using a surveillance 
approach. Serology assays also have a critical role in screening volunteers for vaccine trials 
and convalescent plasma donation, as well as predicting immunity. Although several 
commercial SARS-CoV-2 immunoassays are in common use, evaluation of their sensitivity 
has often used samples from hospitalized patients soon after infection. Knowledge of the 
long-term kinetics of antibody titers and the corresponding effectiveness of commercial 
assays is sparse(1-3). 
Serology assays for SARS-CoV-2 employ viral nucleocapsid (N) or spike protein (S) 
antigens. Because S binds target cells through its receptor binding domain (RBD), it is the 
target of neutralizing antibodies. Therefore, S-based assays may be preferable to N-based 
assays for the assessment future re-infection risk(4). This premise is based on the 
assumptions (1) that neutralizing antibodies constitute a major mechanism of protective 
immunity, and (2) that S-based serology assays accurately predict neutralizing activity. 
Outstanding questions about the use of SARS-CoV-2 serology assays include (1) 
how circulating antibody levels change with time following natural infection and (2) which 
serological assays best predict protective immunity. The prognostic value of antibody 
measurements with respect to reinfection has yet to be demonstrated, and it is important to 
understand post infection serology to enable correlates of protection to be established. We 
present a longitudinal study of mildly symptomatic, non-hospitalised COVID19 positive 
patients during the first few months of convalescence. We compare the ability of four high-
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throughput automated serology assays to diagnose prior SARS-CoV-2 infection and predict 
serum neutralizing activity.  
 
Methods 
 
Participants 
Participants with prior RT-PCR-diagnosed COVID-19 were recruited. Recruits were 
surveyed to determine the date of the positive PCR test, the date of onset of symptoms, and 
if their symptoms required hospitalization. Serum samples were taken at a baseline visit 
(~3.5 to ~8.5 weeks post PCR test), and 2 weeks (visit 2), 4 weeks (visit 3) and 8 weeks 
later (visit 4). In total, 97 participants, who were not hospitalized during the course of their 
illness completed at least 3 visits. The mean age of the participants was 44.2 years (21 – 65 
y), with 70 female (72% of cohort) participants.  At visit 1 (baseline), the average number of 
days between PCR test and visit 1 (baseline) was 40.8 days (24 – 61 days); at visit 2 (2 
weeks post-baseline), the average number of days post-PCR test was 55.1 days (40 – 79 
days); at visit 3 (4 weeks post-baseline), the average number of days post-PCR test was 
69.8 days (55 – 95 days); at visit 4 (8 weeks post-baseline), the average number of days 
post-PCR test was 98.4 days (85 – 110 days). Ethical approval was obtained for this study to 
be carried out through the NHS Lothian BioResource.  All recruits gave written and informed 
consent for serial blood sample collection. De-identified sample were shipped to the 
Rockefeller University whose IRB reviewed and approved the study. 
High throughput automated serology assays 
Four commercial assays, that employ either S or N protein antigens and are designed for 
high throughput in healthcare settings were used. All the assays generate a qualitative 
positive/negative result based on assay-dependent signal thresholds. The Abbott SARS-
CoV-2 IgG assay detects anti-N IgG using a two-step chemiluminescent microparticle 
immunoassay (CMIA) method with an acridinium-labelled anti-human IgG. The DiaSorin 
SARS-CoV-2 IgG assay is also a two-step CMIA method targeting undisclosed epitopes in 
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article/doi/10.1093/infdis/jiaa659/5952470 by U
niversity of D
undee user on 11 N
ovem
ber 2020
 
 6 
the SARS-CoV-2 S protein and employs an isoluminol conjugated anti-human IgG. The 
Roche Anti-SARS-CoV total antibody assay is a two-step bridging electrochemiluminesent 
immunoassay (ECLIA) using ruthenium-labelled and biotin conjugated N protein. The 
Siemens SARS-CoV-2 total antibody assay is a one-step bridging CLIA method that detects 
antibodies against the RBD, using acridinium and biotinylated S1 RBD. Assays were 
performed on the Abbott Architect and DiaSorin Liason platforms (NHS Lothian), and the 
Roche Elecsys (NHS Lanarkshire) and Siemens Atellica (NHS Tayside) platforms. Serum, 
collected and stored according to the manufacturer’s recommendations, was used in all 
cases.  
 
SARS-CoV-2 Neutralization assays 
To measure neutralizing activity, sera, beginning with a 1:12.5 dilution, were five-fold serially 
diluted in 96-well plates over four dilutions. Thereafter, approximately 5x103 infectious units 
of an HIV-1NLΔEnv-NanoLuc/SARS-CoV-2 pseudotype virus were mixed with the serum 
dilutions at a 1:1 ratio and incubated for 1 hour at 37 degrees. The mixture was then added 
to 293T/ACE2cl.22 target cells(5) plated at 1x104 cells/well in 100 µl medium in 96-well 
plates the previous day. Thus, the final starting serum dilution was 1:50. Cells were cultured 
for 48h and harvested for NanoLuc luciferase assays, as previously described(5). 
Results 
The cohort consisted of participants who were not hospitalised during the course of their 
illness and were therefore relatively mildly symptomatic. Approximately 70% of people 
reported at least one of the 3 main WHO -identified symptoms, namely fever, cough and 
anosmia. The most common of symptom was anosmia and the majority of participants 
reported the presence of 2 of these 3 symptoms (Table 1). Serum samples were collected 
from 97 participants at ~4 weeks (visit 1), 6 weeks (visit 2) and 8 weeks (visit 3) post 
diagnosis (by RT-PCR). Additionally, serum was collected from a subset (28 of the 97 
participants) at ~12 weeks post diagnosis (visit 4).  
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We compared the diagnostic sensitivity of 4 high throughput SARS-CoV-2 serology 
assays that are in routine use in hospital settings. Each assay gives a qualitative positive or 
negative result, based on assay specific thresholds, and sensitivities were calculated for 
each assay using these thresholds. Inter and intra-assay analytical precision for each assay 
is detailed in Supplementary Table 1. To account for the differences in time post PCR 
diagnosis that participants made their first visit, sensitivity across a 20 day rolling time 
window was calculated. The Abbott, Roche and Siemens assays all had sensitivities of 95 to 
100% at 21-40 days post PCR-positive test, while the DiaSorin assay had a lower sensitivity 
of 85% (Figure 1A). However, the relative sensitivities of the assays changed with time. 
Specifically, the sensitivity of the Abbott assay declined to 85% in the 61-80 day window, 
and 71% at >81 days post diagnosis (Figure 1A). Conversely, the sensitivities of the other 
assays were maintained or increased over time (Figure 1A). In terms of intra-individual 
change, 14/91 participants that were positive on the Abbott assay at visit 1 were negative by 
visit 3 or 4, whereas none of the participants with a positive result at visit 1 on the other 
assays became negative at visit 3 or 4. For the DiaSorin assay, 2 participants that were 
negative at visit 1 were positive at visit 3 (both participants had an equivocal result at visit 1, 
and showed a small increase above the assay threshold at visit 3). In the Siemens assay, 3 
participants were consistently negative, and in the Roche assay only a single participant was 
negative at each visit.  
 
The serological assays give a quantitative assessment of antibody titer as well as a 
threshold-based positive/negative result. We next analysed changes in the quantitative 
results over time for each platform (Figure 1 B, C). Mean antibody titers decreased in the 
Abbott assay at visits 2 and 3 compared to visit 1 (Figure 1B) but increased in the DiaSorin 
and particularly the Roche assays and remained approximately constant in the Siemens 
assay (Figure 1 B). Notably, 79 out of 97 (81%) of participants showed a decrease in 
antibody titer on the Abbott platform, while 82/97 (85%) showed an increase on the Roche 
assay, despite the fact that both assays detect N-specific antibodies (Figure 1 B, C). 
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Negative or positive change was approximately equally likely in the S-based assays; 
specifically, 57% and 47% of intra-individual changes were negative for the DiaSorin and 
Siemens assays respectively (Figure 1 B, C). 
We measured neutralizing activity in serum samples from the first 3 visits for 80 of 
the 97 participants using a SARS-CoV-2 pseudotyped virus neutralization assay that is 
amenable to high throughput and does not require a BSL-3 facility. This assay employs HIV-
1-based virions carrying a nanoluc luciferase reporter, pseudotyped with the SARS-CoV-2 
spike protein. Neutralization titers obtained using these pseudotyped particles correlate well 
with titers obtained using neutralization of authentic SARS-CoV-2(5). Moreover, this assay 
has been successfully applied for analysis of convalescent plasma samples and in a 
campaign to identify potent human monoclonal antibodies(6, 7). Consistent with our 
analyses of other cohorts(6, 7), a broad range of neutralizing titers were evident in sera 
collected from 80 participants at three timepoints (Figure 2A). In samples collected at visit 1, 
the neutralizing activity, as determined by half-maximal neutralizing titer (NT50), ranged from 
<30 to 4300, with a geometric mean of 234 (arithmetic mean was 411) (Figure 2A, red 
symbols). Consistent with other cohorts (6, 7) 34/80 (42%) had NT50 of less than 250 while 
only in 11/80 participants (14%) had NT50 values higher than 1000.  
NT50 values measured at each timepoint for individual participants correlated with 
each other, although there was divergence in NT50 values over time (Figure 2 A inset). 
Notably, neutralizing activity decreased at each time point for the majority of participants 
(Figure 2 A, blue and green symbols). Overall, the decrease in median NT50 was ~25% per 
two-week sampling interval, resulting in a 45% reduction in NT50 over the 4 weeks between 
visit 1 and visit 3 (Figure 2B). As a result, distribution of NT50 values the cohort differed 
between visits (Figure 2C). The relative decline in NT50  between visits 1 and 2 versus visits 
2 and 3 did not differ significantly, and the majority of participants exhibited a similar relative 
decrease in neutralizing activity over time, regardless of their initial NT50 values or the 
number of days post PCR at visit 1, suggesting exponential decay (Figure 2D). 
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 9 
NT50 values at each sampling timepoint were poorly correlated with age 
(Supplementary Figure 1A), and no correlation was observed between age and NT50 decay 
with time. As has been previously reported, there was a trend toward lower NT50 values in 
females than in males(6, 7), but there was no difference between sexes in NT50 decay with 
time (Supplementary Figure 1B). Individual clinical parameters such as GI symptoms, fever 
or recovery time, did not predict NT50, serological values or decay parameters for any 
antibody measurement.  
Next, we compared neutralizing activity in serum with quantitative results obtained 
from the serological assays. Analysis of combined results from the three visits by 80 
participants revealed a significant correlation between any combination of two serological 
assays (Supplementary Figure 2). However, stronger correlations were observed between 
the two S-based assays, Siemens and DiaSorin (r=0.92, p<0.0001) and between the two N-
based assays Abbott and Roche (r=0.81, p<0.0001), The S-based assays correlated less 
well, but significantly (p<0.0001), with the N-based assays (Supplementary Figure 2).  
All the serological assays gave quantitative values that correlated with NT50 
measurements, but as expected, the S-based assay measurements correlated more closely 
with NT50 measurements (Figure 3A-D). The S1/S2-based DiaSorin assay was the best 
predictor of NT50 (r=0.84, p<0.0001, Figure 3A), followed by the RBD-based Siemens assay 
(r=0.74, p<0.001, Figure 3B), the N-based Abbott assay (r=0.69, p<0.0001, Figure 3C) and, 
lastly, the Roche assay (r=0.56, p=0.0001, Fig3D).  
The correlation between NT50 and the individual serological assays was best at the 
first visit and deteriorated to some extent thereafter (Figure 3A-D, see color-coded r-values 
in individual graphs, p<0.0001 for all correlations), The decrease in the strength of 
correlation might, in part, be attributable to the fact that later sampling timepoints have more 
samples with lower NT50 values, which may reduce measurement precision. The magnitude 
of the deterioration in the predictive value differed between serological assays, with the S-
based assays exhibiting larger decreases in correlation coefficients (r=0.89 and 0.83 at visit 
1, versus r=0.83 and 0.71 at visit 3 for DiaSorin and Siemens assays respectively Figure 3A-
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D), Despite the increasing disparity over time, the DiaSorin assay was clearly superior at 
predicting NT50 at all visits (Figure 3A-D). 
Interestingly, comparison of the extent of change in neutralization activity over the 4-
week observation interval with the concomitant change in values obtained using serological 
assays, revealed only minimal correlation (Figure 4A-D, supplementary Figure 3). Notably, in 
most participants, the decline in serum neutralizing activity was clearly greater than the 
decline in antibody titer measured using any serological assay (Figure 4A-D supplementary 
Figure 3). Even for the Diasorin assay, which gave the best prediction of neutralizing activity 
at each time point (Figure 4A), declines in neutralizing activity were not well predicted by 
declines in Diasorin assay measurements (Figure 4A, supplementary Figure 3). While both 
the Abbott assay and the NT50 measurements exhibited declining antibody titers with time, 
the magnitudes of these declines did not correlate with each other (Figure 4D, 
supplementary Figure 3). 
 
Discussion 
Serological assays for infectious agents have two major and distinct uses, namely (1) 
to diagnose chronic infections (e.g. HIV-1) and (2) to determine past infection or 
immunisation status (e.g. measles, VZV) which may be able to predict immunity from future 
infection. The use of SARS-CoV-2 serological assays requires understanding of how these 
assays perform in populations over time. During the current SARS-CoV-2 pandemic it has 
become clear that the magnitude of serologic immune responses is highly variable(6, 7). 
Nevertheless, the vast majority of individuals with a PCR-confirmed SARS-CoV-2 infection 
generate antibodies at a sufficient level for diagnosis of recent infection(8). A number of high 
throughput commercial assays have been deployed for SARS-CoV-2 antibody testing, and 
evaluated mostly using hospitalized participants(9, 10). Non-hospitalised patients with mild 
disease typically have lower levels of antibodies than hospitalized patients with severe 
illness(11-15), Differences in antibody titers between individuals may be driven in part by 
differences in antigen exposure. However, several variables, variable viral load trajectories, 
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variable time of diagnosis and sampling relative to infection, variable sampling efficiency 
using swabs, and variable relationship between nasal viral load and systemic antigen 
exposure would make relationships between viral load and antibody responses difficult to 
establish.  
Using our cohort of non-hospitalized participants with mild disease, all four assays 
evaluated herein had sensitivities at visit 1 (an average of 40.8 days after PCR testing) that 
were comparable those reported using hospitalised patients(16). This would therefore make 
all four assays suitable for the detection of COVID-19 antibodies shortly after infection as a 
confirmatory test for diagnostic purposes, when used in conjunction with RT-PCR assays 
and clinical history. However, differences in assay diagnostic sensitivity become apparent at 
later time points. Specifically, the sensitivity of the widely used Abbott assay declined with 
time, to ~70% at >81 days post PCR. Consequently, this assay is not appropriate for 
seroprevalence studies, for identification of SARS-CoV-2 naive vaccine trial participants, or 
for investigation of individuals presenting with long term chronic symptoms. Altering the 
positive/negative threshold, may mitigate this issue(17), but would not ultimately alter the 
downward trend in assay signal over time. Notably our study is one of the few that would 
capture this information, as most other studies have examined seroconversion at early time 
points(14, 18-20). Reasons for the differences in assay performance over time are unclear 
but cannot be attributed solely to the choice of antigen. Although other studies have reported 
an inherent difference in the dynamics of S versus N antibodies(21) our findings do not 
support this contention, during the first ~100 days of convalescence. Both Abbott and Roche 
assays employ the N-proteins as an antigen, but Abbott assay titers decline while those in 
the Roche assay increase during this time period. One possible explanation for this 
difference is the use of an antigen bridging approach in the Roche assay, where declines in 
the total amount of antibody might be compensated by increases in affinity or avidity as 
antibodies mature through somatic hypermutation. Alternatively, it is possible that the range 
of N epitopes recognized by sera might change with time. Whatever the explanation, it is 
clear that that the trajectories of antibody titers measured using assays based on recognition 
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of the same or related antigens can differ(22-25). Overall, given their superior sensitivity at 
each of the time points investigated thus far, the Siemens and Roche assays appear most 
appropriate for diagnosis of recent SARS-CoV-2 infection, and would report a higher 
population prevalence than Abbott or DiaSorin assays in the 1 to 4 month post infection 
period. 
Serological assays that serve a diagnostic function are likely optimized for 
sensitivity/specificity rather than for dynamic range, Thus, a quantitative signal in a high 
throughput serological assay might not correspond linearly with antibody titer. Neverthless, 
convalescent plasma is being used therapeutically, with unit selection based on titers 
measured using serological assays (26). Additionally, because vaccine or infection elicited 
neutralizing antibodies will likely confer protection against SARS-CoV-2 infection, it was of 
interest to evaluate the potential ability of serological assays to predict neutralizing antibody 
titer. While the Roche assay exhibited the best diagnostic sensitivity during this time period, 
it had the lowest ability to predict neutralizing antibody titer. This finding might be expected, 
as neutralizing antibodies are directed to the S protein while N-specific antibodies are not 
expected to be neutralizing. The DiaSorin assay best predicted neutralizing titers, and 
marginally outperformed the Siemens assay in this regard, perhaps because the dominant 
neutralizing and/or S-binding activity in some sera is provided by antibodies that recognize 
epitopes outside the RBD(27, 28). It is important to recognize however, that many S-binding 
antibodies are not neutralizing – measurements of S-binding antibodies remain correlates of, 
and not direct measures of, neutralizing antibodies(7).  
Differences in the mechanism of detection likely affects the relationship between 
antibody titers and assay signal output. Changes in the abundance of different antibody 
classes over time could also differentially affect readout in serological assays (e.g. IgM is 
polyvalent and short-lived and might give greater signals in bridging assays). Nevertheless, 
changes in antibody class composition do not easily explain the trends that we observe, for 
instance IgG is a longer lived antibody response and the Abbott assay is IgG specific, but 
Abbot assay titers were the least stable of those evaluated. Neutralization is not specific for 
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any antibody isotype/subclass and neutralizing titers will reflect the combined activity of all 
neutralizing antibodies in a sample, Again the comparative stability of the IgG response and 
the dominant role of IgG in neutralizing plasma (29) does not comport with the idea that 
changing antibody class abundance could explain declining neutralizing titers. 
Very recent reports have similarly indicated that SARS-CoV-2 neutralizing antibody 
titers decline with time(23, 24), while another study reported that neutralization titers 
remained stable for at least 3 months post infection(30). However, in the latter case 
neutralization titers were inferred based on a serologic ELISA measurement that was 
calibrated using a neutralization assay performed on a small subset of samples. As shown 
herein, neutralizing antibody levels indeed decline in most patients, even when S-binding or 
RBD-binding antibody titers measured in serology assays are maintained. Thus, the 
trajectory of neutralizing antibody levels cannot necessarily be accurately deduced from 
serologic measurements. 
Key future questions include to what degree the titers of neutralizing antibodies, or 
antibodies that simply bind to S or N correlate with protection from reinfection or severe 
disease. Many adults possess circulating antibodies to seasonal hCoVs OC43 and 
229E(31), and children seroconvert to NL63 and 229E before ~3.5 years of age(32). These 
baseline levels increased upon infection, returning to baseline within one year. High levels of 
circulating neutralizing antibody correlated with protection from re-infection (33, 34). 
However, hCoV re-infections occur(34, 35) often within 12 months(36), but with more mild 
illness. Thus, these data suggest that seasonal hCoV immunity wanes with time. For SARS-
CoV and MERS-CoV, antibody responses also decline in the majority of infected 
individuals(37) Indeed, analyses of the decay of SARS-CoV antibodies indicate kinetics 
consistent with those reported herein (38). Moreover, recent studies have documented 
SARS-CoV-2 reinfection (39-41), in one case in the context of waning neutralizing antibodies 
(42). Overall, it seems possible that SARS-CoV-2 reinfection might be common. Importantly 
however, the magnitude and stability of antibody responses to SARS-CoV-2 vaccines might 
be quite different to those following natural infection. Specifically, if the great variability in 
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post infection SARS-CoV-2 antibody levels are indeed a consequence of variable antigen 
exposure, then differences might be mitigated in the context of vaccination. 
If neutralizing antibodies constitute a major protective mechanism against SARS-
CoV-2 infection, then serological assays that use S-based antigens and best predict 
neutralizing titer are the most appropriate for prognostication of immunity. Conversely, if 
other immune mechanisms, such as long-lived memory T-cells play a dominant role in 
protection (43-46), then the optimal choice of antigen for serology assays might differ. 
Because detailed analyses of T-cell responses are not currently feasible in a high throughput 
clinical setting, future work should examine the frequency of reinfection and clinical 
outcomes with detailed longitudinal analyses of serum antibodies to both N and S antigens 
to determine the prognostic value of such measurements.   
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Table 1 Percentage of participants per cohort displaying the three main WHO 
symptoms  
 Fever Cough Anosmia 0 of 3 
symptoms 
1 of 3 
symptoms 
2 of 3 
symptoms 
All 3 
symptoms 
Self-
reported 
recovered 
Reported 
symptom 
65 69 74 1 19 42 35 44 
% 67% 71% 76% 1% 16% 43% 36% 49% 
 
N = 97 for all reported symptoms apart from ―self-reported recovered‖, where only 90 
individuals responded to this survey question 
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Figure legends 
Fig. 1.  Longitudinal analysis of COVID-19 participant sera. (A) Sensitivity of the Abbott, 
DiaSorin, Siemens and Roche serological assays (as indicated) measured in samples 
collected at four different timepoints, as indicated, post PCR test and 95% confidence 
interval. (B) Relative antibody titers for the DiaSorin, Siemens, Abbott and Roche, assays at 
visits 1-3, normalized to visit 1. Horizontal line indicates median value with 95% confidence 
interval. Statistical significance was assessed with the Wilcoxon test. (C) Values for 
DiaSorin, Siemens, Abbott and Roche serological assays for each participant plotted over 
time (each line represents one participant). Assay thresholds are indicated by a dotted 
horizontal line. 
Fig. 2. Neutralization activity in COVID-19 participant sera. (A) Half-maximal 
neutralization titers (NT50s) for each individual participant measured in serum samples 
collected at three different visits, as indicated by color. Inserts show correlation of NT50 
values for samples collected at each visit, the spearman r is indicated (p<0.0001). (B) 
Relative NT50 values in sera obtained at visit 1 to 3, normalized to visit 1. Horizontal line 
represents median with 95% confidence interval. Statistical significance was assessed with 
the Wilcoxon test. (C) Frequency of sera with  NT50 values falling to various quantitative 
categories at each visit. (D) NT50 values for each participant plotted over time (each line 
represents one participant). The limit of detection (LOD) is indicated by a dotted horizontal 
line.  
Fig. 3. Correlation of serology results with neutralization titers. (A-D) Serological assay 
values for the DiaSorin (A), Siemens (B), Abbott (C) and Roche (D) assays versus NT50 
values. Samples collected at each visit are indicated by color and are plotted individually as 
well as on a composite graph. Spearman r for all visits (black) and individual visits are 
indicated (p<0.0001).   
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Fig. 4. Lack of correlation of changes serology results with changes in neutralization 
titers. 
(A-D) Fold-change (visit 1 to visit 3) in serological assay values for the DiaSorin (A), 
Siemens (B), Abbott (C) and Roche (D) assay versus fold-change in NT50 values. Spearman 
r and p-value are indicated.  
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Figure 2 
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Figure 3 
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Figure 4 
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